University of Washington School of Medicine.
Department of Radiation Oncology, University of Washington, Seattle, WA.
Am J Clin Oncol. 2021 Jan 1;44(1):32-42. doi: 10.1097/COC.0000000000000775.
The purpose of this report is to assess the efficacy and adverse event profile of photon-based stereotactic radiosurgery (SRS) compared with fractionated stereotactic radiotherapy (fSRT) for the treatment of uveal melanoma. Primary outcomes include incidence proportions of local control, enucleation, metastatic progression, disease-specific, and overall mortality. Treatment-related toxicities such as incidence proportions of radiation retinopathy, neovascular glaucoma, optic neuropathy, and cataract formation were examined as secondary outcomes. Five-year survival and 5-year local control rates were also assessed.
PubMed, Embase, Web of Science, Scopus, and 2 Cochrane databases were searched up to December 31, 2018. Random effects models were used to calculate pooled incidence proportions of outcome measures. Meta-regression was carried out to explore the potential impact of dose per fraction on local control.
Twenty-four articles with a total of 1745 patients were included in the meta-analysis. There were no statistically significant differences between photon-based fSRT and SRS for all primary, secondary and 5-year outcome measures, including local control (P=0.28), enucleation (P=0.51), and neovascular glaucoma (P=0.40). The 5-year local control rate was 90% (95% confidence interval: 76%, 96%) for fSRT and 89% (70%, 97%) for SRS.
Our meta-analysis showed no difference in tumor control, survival and toxicities, as defined in this paper, between SRS and fSRT for uveal melanoma. Confounding biases remain an expected limitation in this study of novel treatment modalities deployed in rare tumors. Further investigation is needed to validate outcomes and compare stereotactic treatment techniques.
本报告旨在评估与分割立体定向放射治疗(fSRT)相比,光子立体定向放射外科(SRS)治疗葡萄膜黑色素瘤的疗效和不良事件谱。主要结局包括局部控制、眼球摘除、转移进展、疾病特异性和总死亡率的发生率比例。作为次要结局,检查了与治疗相关的毒性,如放射性视网膜病变、新生血管性青光眼、视神经病变和白内障形成的发生率比例。还评估了 5 年生存率和 5 年局部控制率。
检索了 PubMed、Embase、Web of Science、Scopus 和 2 个 Cochrane 数据库,检索时间截至 2018 年 12 月 31 日。使用随机效应模型计算结局测量的合并发生率比例。进行了荟萃回归分析,以探索剂量分割对局部控制的潜在影响。
共有 24 篇文章,总计 1745 例患者纳入荟萃分析。光子 fSRT 和 SRS 在所有主要、次要和 5 年结局测量中,包括局部控制(P=0.28)、眼球摘除(P=0.51)和新生血管性青光眼(P=0.40),均无统计学差异。fSRT 的 5 年局部控制率为 90%(95%置信区间:76%,96%),SRS 为 89%(70%,97%)。
我们的荟萃分析表明,在本文定义的肿瘤控制、生存和毒性方面,SRS 与 fSRT 治疗葡萄膜黑色素瘤没有差异。在这项针对新型治疗方法治疗罕见肿瘤的研究中,混杂偏倚仍然是一个预期的局限性。需要进一步的研究来验证结果并比较立体定向治疗技术。